Regulation of Soluble Insulin-Like Growth Factor II/Mannose 6-Phosphate Receptor in Human Serum: Measurement by Enzyme-Linked Immunosorbent Assay

1999 ◽  
Vol 84 (2) ◽  
pp. 611-617 ◽  
Author(s):  
M. Costello
1988 ◽  
Vol 252 (3) ◽  
pp. 795-799 ◽  
Author(s):  
C Causin ◽  
A Waheed ◽  
T Braulke ◽  
U Junghans ◽  
P Maly ◽  
...  

Human serum and urine contain polypeptides which bind mannose 6-phosphate (M6P) and insulin-like growth factor II (IGF II) and crossreact with antibodies against the M6P/IGF II receptor. These polypeptides are considered to be fragments of the M6P/IGF II receptor. The major Mr approx. 205,000 fragment in serum and urine is about 10 kDa smaller in size than the membrane-associated receptor and is accompanied by minor forms with Mr values ranging from 104,000 to 180,000. The presence of receptor fragments in biological fluids indicates that shedding is one of the mechanisms contributing to the turnover of the M6P/IGF II receptor and that receptor fragments are part of the heterogenous group of serum proteins whic bind IGF II.


1999 ◽  
Vol 84 (2) ◽  
pp. 611-617 ◽  
Author(s):  
Michael Costello ◽  
Robert C. Baxter ◽  
Carolyn D. Scott

The soluble form of the insulin-like growth factor II/mannose 6-phosphate (IGF-II/M6-P) receptor has been detected in serum from a variety of mammalian species. We report the development of a highly sensitive quantitative human IGF-II/M6-P receptor immunoassay. Antibodies raised to receptor purified from a human hepatoma cell line by phosphomannan affinity chromatography were used to develop a specific enzyme-linked immunosorbent assay. In this assay, the serum level of soluble receptor for healthy adult subjects was 0.70 ± 0.23 mg/L. We have shown that soluble receptor is developmentally regulated, with levels in infant (1.12 ± 0.28 mg/L) and prepubertal (1.18 ± 0.6 mg/L) subjects dropping by 40% during adolescence (0.73 ± 0.61 mg/L) and remaining constant throughout adulthood. Further, the receptor is gestationally regulated, with a highly significant association between gestational age and maternal serum receptor levels (r = 0.947; P < 0.0001). Noninsulin-dependent diabetes mellitus (0.98 ± 0.25 mg/L) and insulin-dependent diabetes mellitus (0.98 ± 0.25 mg/L) mildly elevated soluble receptor levels, whereas end-stage renal failure (0.75 ± 0.23 mg/L) and acromegaly (0.79 ± 0.25 mg/L) did not affect receptor levels. Additionally, we have shown that soluble receptor is present in amniotic fluid, but at a 100-fold lower concentration than serum levels. The ability to quantitate soluble IGF-II/M6-P receptor levels in serum and other fluids provides a valuable tool that will help to further elucidate the role of the receptor in human physiology and disease states.


Endocrinology ◽  
1998 ◽  
Vol 139 (9) ◽  
pp. 3886-3895 ◽  
Author(s):  
Silvio Zaina ◽  
Rosalind V. S. Newton ◽  
Mukta R. Paul ◽  
Christopher F. Graham

Sign in / Sign up

Export Citation Format

Share Document